type 2 diabetes

Trial sets up 2020 filing for Poxel’s novel diabetes drug
Trial sets up 2020 filing for Poxel’s novel diabetes drug
Pharmaforum
Poxel
Japan
diabetes
type 2 diabetes
clinical trials
imeglimin
Flag link:
Intarcia licenses Numab's autoimmune therapy
Intarcia licenses Numab's autoimmune therapy
BioCentury
Intarcia
Numab
BD016
type 2 diabetes
Flag link:
AstraZeneca gets FDA expanded approval for Farxiga and Xigduo XR
AstraZeneca gets FDA expanded approval for Farxiga and Xigduo XR
Pharmaceutical Business Review
AstraZeneca
type 2 diabetes
Farxiga
Xigduo XR
FDA
Flag link:
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Pharmaceutical Business Review
Boehringer Ingelheim
Eli Lilly
glimepiride
linagliptin
Tradjenta
type 2 diabetes
clinical trials
Flag link:
Merck bags global rights to NGM NASH drug, plans phase 2b trial
Merck bags global rights to NGM NASH drug, plans phase 2b trial
Fierce Biotech
Merck
NASH
NGM Biopharmaceuticals
type 2 diabetes
clinical trials
MK-3655
Flag link:
FDA Slaps Clinical Hold on Zafgen’s Lead Product Over Safety Concerns
FDA Slaps Clinical Hold on Zafgen’s Lead Product Over Safety Concerns
BioSpace
Zafgen
clinical trials
FDA
diabetes
ZGN-1061
type 2 diabetes
Flag link:
Novo Nordisk’s diabetes pill clears cardiac safety hurdle
Novo Nordisk’s diabetes pill clears cardiac safety hurdle
Pharmaforum
Novo Nordisk
semaglutides
type 2 diabetes
clinical trials
cardiovascular outcomes
Flag link:
Millions left behind as diabetes drives surge in insulin demand
Millions left behind as diabetes drives surge in insulin demand
Reuters
diabetes
type 2 diabetes
insulin
Flag link:
A startup for diabetes patients rolls out a new model: Insurers only pay if the service works
A startup for diabetes patients rolls out a new model: Insurers only pay if the service works
Stat
devices
digital coaching
type 2 diabetes
Virta Health
Flag link:
Questions Raised About Invokana Label Expansion For CV Risk Reduction
Questions Raised About Invokana Label Expansion For CV Risk Reduction
Forbes
Janssen
JNJ
Invokana
type 2 diabetes
Flag link:
Johnson & Johnson bags long-awaited cardiovascular nod for diabetes drug Invokana
Johnson & Johnson bags long-awaited cardiovascular nod for diabetes drug Invokana
Fierce Pharma
JNJ
Invokana
type 2 diabetes
Flag link:
Digital diabetes mavens Novo Nordisk and Sanofi top new patient experience ranking
Digital diabetes mavens Novo Nordisk and Sanofi top new patient experience ranking
Fierce Pharma
patients
patient experience data
Sanofi
Novo Nordisk
type 2 diabetes
Flag link:
AstraZeneca and Ionis target diabetes with antisense approach to regenerating pancreatic cells
AstraZeneca and Ionis target diabetes with antisense approach to regenerating pancreatic cells
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
type 2 diabetes
antisense
Flag link:
Anthem, HealthCore and Novo Nordisk for Partnership to Study Benefits New Type 2 Diabetes Drug Vs Other Available Drugs
Anthem, HealthCore and Novo Nordisk for Partnership to Study Benefits New Type 2 Diabetes Drug Vs Other Available Drugs
CP Wire
Anthem
Novo Nordisk
Ozempic
type 2 diabetes
Flag link:
Anthem, HealthCore and Novo Nordisk for Partnership to Study Benefits New Type 2 Diabetes Drug Vs Other Available Drugs
Anthem
Novo Nordisk
Ozempic
type 2 diabetes
Flag link:
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
CP Wire
Jardiance
Boehringer Ingelheim
Eli Lilly
diabetes
type 2 diabetes
Flag link:
Eli Lilly's diabetes treatment meets main goal in two late-stage studies
Eli Lilly's diabetes treatment meets main goal in two late-stage studies
Reuters
Eli Lilly
Ultra Rapid Lispro
Humalog
diabetes
type 1 diabetes
type 2 diabetes
Flag link:
Lilly Licenses Chugai Pharma's Oral Diabetes Drug for $50 Million Upfront
Lilly Licenses Chugai Pharma's Oral Diabetes Drug for $50 Million Upfront
BioSpace
Eli Lilly
Chugai
OWL833
type 2 diabetes
Flag link:
Farxiga Meets One Primary Endpoint in Large Ph III Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes
Farxiga Meets One Primary Endpoint in Large Ph III Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes
CP Wire
AstraZeneca
Farxiga
Dapagliflozin
clinical trials
type 2 diabetes
cardiovascular disease
Flag link:
How One Class Of Diabetes Medications May Lead To Flesh-Eating Genital Infections
How One Class Of Diabetes Medications May Lead To Flesh-Eating Genital Infections
Forbes
FDA
type 2 diabetes
SGLT2 inhibitor
Flag link:

Pages